Effect of monovalent measles and trivalent measles-mumps-rubella vaccines at various ages and concurrent administration with hepatitis B vaccine.
To determine the most suitable vaccination schedule in developing countries, a study was conducted to reevaluate the immunogenicity of monovalent measles vaccine and trivalent measles-mumps-rubella vaccine at different ages. The success rate of measles vaccination was 84% at 9 months, 88% at 12 months and 100% at 15 months of age. Vaccination with measles vaccines at 9 and 15 months of age was also 96% immunogenic. Most vaccinees (16 of 17) not responding to the first measles vaccine before 1 year of age developed measles antibody with another shot of vaccine after 15 months of age. Trivalent measles-mumps-rubella vaccine worked well in children ages 14 to 18 months. Administering trivalent vaccine and hepatitis B vaccine concurrently at 1 year of age, rubella and mumps antibodies developed in more than 95% of vaccinees, while measles antibody was detected in 88%. Responses to hepatitis B vaccine in this situation were good; 89% of vaccinees developed antibody against hepatitis B surface antigen (greater than or equal to 10 mIU/ml) and the geometric mean titer was 362.49 mIU/ml. In summary vaccination twice at 9 and 15 months is effective and is a useful regimen in developing countries where measles is still endemic. Trivalent vaccine and hepatitis B vaccine will not interfere with each other when given together at 1 year of age.
Huang
L M
LM
Department of Pediatrics, National Taiwan University Hospital, Taipei, Republic of China.
Lee
C Y
CY
Hsu
C Y
CY
Huang
S S
SS
Kao
C L
CL
Wu
F F
FF
Lee
C C
CC
Chang
H S
HS
Huang
L Y
LY
D000367:Age Factors; D000914:Antibodies, Viral / Q000032:analysis*; D003906:Developing Countries; D004341:Drug Evaluation; D004347:Drug Interactions / Q000276:immunology; D006509:Hepatitis B / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008457:Measles / Q000276:immunology*; D009107:Mumps / Q000276:immunology*; D011446:Prospective Studies; D012409:Rubella / Q000276:immunology*; D013624:Taiwan; D014611:Vaccination / Q000379:methods*; D014765:Viral Vaccines / Q000276:immunology
D000914:Antibodies, Viral; D014765:Viral Vaccines